Loading Valuation Snapshot...
Stock DNA
Pharmaceuticals & Biotechnology
INR 8,683 Cr (Mid Cap)
56.00
33
0.00%
-0.01
24.58%
13.74
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
Returns Beta
Beta has not been calculated since enough price history is not available
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.68%
ROCE (avg)
29.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
56
Industry P/E
33
Price to Book Value
13.87
EV to EBIT
41.43
EV to EBITDA
35.01
EV to Capital Employed
14.01
EV to Sales
7.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
33.82%
ROE (Latest)
24.58%
Technicals key factors
Indicator
Weekly
Monthly
No records
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 14 Schemes (2.44%)
FIIs
Held by 43 FIIs (1.04%)
Promoter with highest holding
Ankurbhai K Mehta (22.0%)
Highest Public shareholder
Sepia Investments Limited (19.76%)
Individual Investors Holdings
4.83%
About Corona Remedies Ltd 
Corona Remedies Ltd
Mid Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






